Because of the role of class I HDACs in repressing ER expression and promoting EMT, there may also be value in the preclinical investigation of sequential class I HDAC inhibition followed by aromatase inhibition or selective estrogen receptor modulator (SERM) treatment in TNBC or other HR-negative breast cancers. Here, HDAC9 is linked to breast carcinoma.